2026-03-10T15:16:08Z https://soar-ir.repo.nii.ac.jp/oai

oai:soar-ir.repo.nii.ac.jp:00003826 2022-12-14T04:39:56Z 461:462

Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C Yoneda, Suguru Umemura, Takeji Joshita, Satoru Ichijo, Tetsuya Matsumoto, Akihiro Yoshizawa, Kaname Katsuyama, Yoshihiko Ota, Masao Tanaka, Eiji The definitive version is available at www.blackwell-synergy.com chemokines core interferon sensitivity determining region MIP-1 beta pegylated interferon ribavirin Aim: Serum chemokine levels and amino acid substitutions in the interferon-sensitivity determining region (ISDR) and core region have been associated with treatment outcome of pegylated interferon and ribavirin therapy in genotype 1 hepatitis C virus (HCV)-infected patients. The present study was conducted to clarify the association between serum chemokines and treatment outcome in patients with chronic HCV-1 infection in a Japanese cohort. Methods: A total of six serum chemokines were quantified before, during and after pegylated interferon and ribavirin treatment in 79 genotype 1 chronic HCV patients using a multiple bead array system. Viral ISDR and core region variants were determined by direct sequencing. Results: The baseline serum levels of eotaxin, IP-10 and RANTES were significantly higher in chronic HCV patients than in controls. High levels of eotaxin and macrophage inflammatory protein (MIP)-1 beta before therapy and more than two mutations in the ISDR were associated with a sustained virological response, and patients with more than two mutations in the ISDR also had significantly higher MIP-1 beta levels. Receiver-operator curve analysis showed a 77% sensitivity and 73% specificity for predicting an SVR using MIP-1 beta values. Conclusion: Serum MIP-1 beta levels may predict the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR. WILEY-BLACKWELL 2011-06 eng journal article AM http://hdl.handle.net/10091/16244 https://soar-ir.repo.nii.ac.jp/records/3826 https://pubmed.ncbi.nlm.nih.gov/21504519 21504519 https://doi.org/10.1111/j.1872-034X.2011.00802.x 10.1111/j.1872-034X.2011.00802.x 1386-6346 AA11140867 HEPATOLOGY RESEARCH 41 6 587 593 https://soar-ir.repo.nii.ac.jp/record/3826/files/Serum_Chemokine_Levels_Are_Associated_Outcome_ Pegylated_Interferon.pdf application/pdf 210.2 kB 2015-09-24